secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001689548-25-000110
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis reports Q3 net loss $73.9M; ulixacaltamide Phase 3 positive; pro forma cash ~$956M
--------------------------------------------------------------------------------

- Ulixacaltamide met primary endpoints in both Essential3 Phase 3 studies for essential tremor; pre-NDA meeting with FDA scheduled Q4 2025.
- Q3 net loss $73.9M vs $51.9M YoY; R&D expenses rose to $65.8M from $41.9M.
- Cash and marketable securities $389.2M at Sept 30; October public offering added ~$567M net, extending runway into 2028.
- Vormatrigine POWER1 study for focal onset seizures fully enrolled; topline expected 1H 2026.
- Relutrigine interim analysis for SCN2A/SCN8A DEEs planned Q4 2025; if positive, NDA submission possible early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/0001689548-25-000110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/prax-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001689548-25-000110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer